RJA
MDCO

Raymond James & Associates’s Medicines Co MDCO Stock Holding History

Raymond James & Associates’s Portfolio MDCO Stock Details MDCO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-7,818
Closed -$287K – 3773
2018
Q2 		$287K Hold
7,818
– – ﹤0.01% 3053
2018
Q1 		$258K Sell
7,818
-3,139
-29% -$98.1K ﹤0.01% 2987
2017
Q4 		$300K Sell
10,957
-2,214
-17% -$68.2K ﹤0.01% 2835
2017
Q3 		$488K Sell
13,171
-42
-0.3% -$1.55K ﹤0.01% 2500
2017
Q2 		$502K Buy
13,213
+1,112
+9% +$49.5K ﹤0.01% 2421
2017
Q1 		$592K Buy
12,101
+5,527
+84% +$252K ﹤0.01% 2280
2016
Q4 		$223K Buy
6,574
+271
+4% +$9.61K ﹤0.01% 2833
2016
Q3 		$238K Buy
+6,303
New +$238K ﹤0.01% 2765
2014
Q2 		– Sell
-33,277
Closed -$946K – 2249
2014
Q1 		$946K Buy
33,277
+8,304
+33% +$275K 0.01% 1459
2013
Q4 		$964K Buy
24,973
+1,764
+8% +$63.1K 0.01% 1353
2013
Q3 		$778K Buy
+23,209
New +$739K 0.01% 1382

Other funds holding MDCO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's MDCO Position: Q3 2018 in Review

Raymond James & Associates sold out of Medicines Co (MDCO) in Q3 2018, closing a stake of 7,818 shares — an estimated $287K sold.

Raymond James & Associates first reported a position in MDCO in Q3 2013 and held it in 11 quarters. The position peaked at $964K in Q4 2013. 184 funds tracked by Wall St. Rank hold MDCO as of Q3 2018.

  • Raymond James & Associates reported no remaining Medicines Co position as of Q3 2018 after selling out during the quarter.
  • Raymond James & Associates sold 7,818 Medicines Co shares in Q3 2018, an estimated $287K.
  • Raymond James & Associates first reported a position in Medicines Co in Q3 2013 and held it in 11 quarters.
  • Raymond James & Associates's Medicines Co position peaked at $964K in Q4 2013.
  • 184 funds tracked by Wall St. Rank held Medicines Co as of Q3 2018.

Based on Raymond James & Associates's 13F filing for Q3 2018, filed 14 Nov 2018.